Categories
Journal of Drugs in Dermatology

Sulodexide shows promise in the treatment of oral erosive/ulcerative lichen planus – Washington Whispers

Sulodexide shows promise in the treatment of oral erosive/ulcerative lichen planus – Washington Whispers – Brief Article

This open non-randomized trial compared the effect of heparinoid sulodexide systemically compared with topical cyclosporine on chronic oral erosive/ulcerative lichen planus. Sulodexide is composed of 80% heparin and 20% dermatan sulfate. Preliminary studies have shown that low molecular weight heparin may produce partial resolution of lichen planus with cutaneous and oral involvement.

Twenty patients were non-randomly divided into two subgroups, with each group having comparable numbers of men/women, HCV status, and oral lesions of comparable pain and extent. The sulodexide group received intramuscular treatment (600 units) once, followed by oral doses of 250 units twice daily for 1 month. The comparison study group received oral cyclosporine 1 cc (100 mg/cc) three times daily as an oral rinse for 3 minutes, for 1 month. Patients were asked to assess their level of time during the trial, and a physician assessed clinical improvement.

Nine of the 10 patients in the sulodexide group reported resolution of pain within the first week and had total clinical resolution after 20-25 days. In the cyclosporine group, pain resolved after 10-70 days in all patients, with clinical resolution occurring in all patients after a mean of 36 days. At 3 and 5 month follow-ups, patients of both subgroups maintained remission of pain and erosion/ulceration in the absence of continued drug therapy.

Femiano F, et al. Oral erosive/lichen planus: preliminary findings in an open trial of sulodexide compared with cyclosporine therapy. Int J Dermn 2003; 42:308-311.

COPYRIGHT 2003 Journal of Drugs in Dermatology

COPYRIGHT 2003 Gale Group